Standard Biotools (LAB) Total Non-Current Liabilities (2010 - 2026)

Standard Biotools (LAB) has 17 years of Total Non-Current Liabilities data on file, last reported at $73.5 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 39.47% year-over-year to $73.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.5 million (down 39.47% YoY) and the FY2025 annual result came in at $142.2 million, up 1.93% from the prior year.
• Total Non-Current Liabilities slipped to $73.5 million in Q1 2026 per LAB's latest filing, from $142.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $248.3 million in Q1 2022 and bottomed at $73.5 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $158.7 million (2023), against an average of $159.0 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities jumped 37.29%; it then sank 39.47% in 2026.
• Tracing LAB's Total Non-Current Liabilities over 5 years: stood at $159.6 million in 2022, then dropped by 0.48% to $158.8 million in 2023, then decreased by 12.12% to $139.6 million in 2024, then climbed by 1.93% to $142.2 million in 2025, then tumbled by 48.3% to $73.5 million in 2026.
• Per Business Quant, the three latest LAB Total Non-Current Liabilities figures stand at $73.5 million (Q1 2026), $142.2 million (Q4 2025), and $138.8 million (Q3 2025).

Peer Comparison